Fibulin 5, Recombinant, Human (Fibulin-5, FIBL-5, Developmental Arteries and Neural Crest EGF-like Protein, Dance, Urine p50 Protein, UP50, FBLN5, DANCE, UNQ184/PRO210)

Fibulin 5, also known as DANCE and EVEC, is a secreted 55kD matricellular glycoprotein that plays an important role in elastic fiber network assembly and angiogenesis. Mature human Fibulin 5 contains an N-terminal EGF-like domain with an RGD motif, a 44aa spacer region, five more tandem EGF-like domains, and a 115aa Fibulin-like C-terminal region. Mature human Fibulin 5 shares 95% aa sequence identity with mouse and rat Fibulin 5. Fibulin 5 i s expressed by smooth muscle cells and endothelial cells of the developing asculature as well as by migrating neural crest cells and l unginterstitial fibroblasts. It is downregulated in the adult vasculature but is re-expressed at aortic branching points, in the uterus, and at sites of mechanical or at herosclerotic injury. The RGD motif of Fibulin 5 binds to several cell surface Integrins including aVb3, aVb5, a9b1, a4b1, and a5b1. The calcium-dependent binding of Fibulin 5 to elastic fibers serves to anchor cells to the extracellular matrix. Fibulin 5 promotes elastic fiber assembly and maturation by organizing Tropoelastin, LTBP-2, and the crosslinking lysyl oxidase-like enzymes LOXL1, 2, and 4 along Fibrillin microfibrils. In aged mice with decreased tissue elasticity, proteolytic removal of the N-terminal EGF-like domain prevent s Fibulin 5 from interacting with Fibrillin-1 microfibrils. Fibulin 5 functions as an angiogenesis inhibitor by inhibiting vascular smooth muscle proliferation a migration and by limiting vascular sprouting. Fibulin 5 is downregulated in many malignancies. When experimentally re-expressed, however, Fibulin 5 enhances tumor cell invasiveness and cooperates with TGF-b i n initiating and promoting epithelial-mesenchymal transition (EMT). Defects in Fibulin 5 expression or function can result in a loss of connective tissue Integrity, cardiac elasticity, and ability to remodel the vasculature after injury.\n\nSource:\nRecombinant human Fibulin 5, Cho-derived, Gln24-Phe448, with a C-terminal 6-His tag\n\nSDS-PAGE: 60-66kD, reducing conditions\n\nActivity: Measured by the ability of the immobilized protein to enhance the adhesion of human umbilical vein endothelial cells (HUVEC). When 5x10e4 cells per well are added to rhFibulin-5 coated plate, cell adhesion is enhanced in a dose dependent manner after 60 minutes at 37 degrees C. ED50 for this effect is typically 0.1-0.4ug/ml.\n\nStorage and Stability:\nLyophilized powder may be stored at -20 degrees C. Stable for 12 months at -20 degrees C. Reconstitute with sterile buffer or ddH2O. Aliquot to avoid repeated freezing and thawing. Store at -20 degrees C. Reconstituted product is stable for 6 months at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

F4350-37

Size

25ug

Form

Supplied as a lyophilized powder from a 0.2um filtered solution in PBS, EDTA.

Purity

~95% (SDS

References

1. Yanagi sawa, H. et al. (2009) J. Cell. Commun. Signal. 3:337. 2. Nakamura, T. et al. (1999) J. Biol. Chem. 274:22476. 3. Kowal, R.C. et al. (1999) Circ. Res. 84:1166. 4. Kuang, P.-P. et al. (2003) Am. J. Physiol. Lung Cell. Mol. Physi ol . 285:L1147. 5. Spencer, J.A. et al. (2005) Proc. Natl. Acad. Sci. 102:2946. 6. Nakamura, T. et al. (2002) Nature 415:171. 7. Lomas, A.C. et al. (2007) Biochem. J. 405:417. 8. Yanagi sawa, H. et al. (2002) Nature 415:168. 9. Wachi , H. et al. (2008) J. Biochem. 143:633. 10. Hirai, M. et al. (2007) J. Cell Biol. 176:1061. 11. Hirai, M. et al. (2007) EMBO J. 26:3283. \n12. Sullivan, K.M. et al. (2007) Lab. Invest. 87:818. 13. Lee, Y.-H. et al. (2008) Carcinogenesis 29:2243. 14. Loeys, B. et al. (2002) Hum. Mol. Genet. 11:2113. 15. Schiemann, W. P. et al. (2002) J. Biol. Chem. 277:27367.